Rain Therapeutics Inc. (RAIN)
Jan 26, 2024 - RAIN was delisted (reason: acquired by Pathos AI)
1.210
-0.020 (-1.63%)
Inactive · Last trade price
on Jan 25, 2024
Company Description
As of January 26, 2024, operates as a subsidiary of Pathos AI, Inc.
Rain Therapeutics Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Apr 23, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 63 |
| CEO | Avanish Vellanki M.B.A. |
Contact Details
Address: 8000 Jarvis Avenue, Suite 204 Newark, California 94560 | |
| Phone | (510) 953-5559 |
| Website | rainthera.com |
Stock Details
| Ticker Symbol | RAIN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001724979 |
| CUSIP Number | 75082Q105 |
| ISIN Number | US75082Q1058 |
| Employer ID | 82-1130967 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Avanish Vellanki M.B.A. | Co-Founder, Chief Executive Officer and Chairman |
| Dr. Robert C. Doebele M.D., Ph.D. | Co-Founder, Chairman of Scientific Advisory Board, President and CSO and Chief Medical Officer |
| Josephine Bruce | Principal Financial and Accounting officer |
| Theresa O'Connell M.S. | Director of Corporate Development and Operations |
| Erik Atkisson | General Counsel and Chief Compliance Officer |
| Charmi Turner | Vice President of People and Culture |
| Vijaya Tirunagaru Ph.D. | Senior Vice President and Head of Research |
| Dr. Nora Ku M.D. | MD and Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 29, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jan 26, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jan 26, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jan 26, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jan 26, 2024 | POS AM | Post-Effective amendments for registration statement |
| Jan 26, 2024 | 8-K | Current Report |
| Jan 26, 2024 | SC 14D9/A | Filing |
| Jan 26, 2024 | SC TO-T/A | Filing |
| Jan 26, 2024 | 25-NSE | Filing |
| Jan 22, 2024 | SC 14D9/A | Filing |